Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Melero and colleagues discuss the current landscape of immunotherapy combinations, ongoing clinical studies and the translational implications for efficacy and safety across tumor types.
Stanley and Abdel-Wahab review the latest insights into the biological mechanisms of RNA splicing dysregulation in cancer and the emerging landscape of therapeutic opportunities in this field.
Llovet and colleagues review recent advances in hepatocellular carcinoma therapy and the clinical workflows for the selection and monitoring of patients undergoing systemic therapies and immunotherapy.
Hosein et al. discuss the current therapeutic landscape in pancreatic cancer as well as the translational and clinical implications and the challenges to overcome.
Hwang and colleagues discuss recent advances and current challenges in developing immunotherapies for pediatric brain cancer, as well as the clinical implications of ongoing and completed studies.
Ding and colleagues discuss the era of pan-cancer analysis, covering the fundamental insights gained, unique opportunities and challenges, and the future of such approaches in the basic and clinical space.
Melenhorst and colleagues review the current status of chimeric antigen receptor T cell therapies, focusing on the rapid progress achieved in this area of immunotherapy, but also the challenges to be overcome.
Pasha and Turner review recent insights into the role of intratumoral heterogeneity in therapeutic resistance in metastatic breast cancer and discuss forward-looking strategies to overcome this hurdle.
Scatiltri and colleagues review the paradigms of targeting PI3K in solid tumors in the clinic, including the progress so far in developing effective inhibitors as well as clinical limitations due to toxicity and therapeutic resistance.
Passaro and colleagues discuss recent advances in treating EGFR-mutant lung cancer, including methods for detecting disease and tracking therapy response, developments in understanding of resistance mechanisms and ongoing clinical trials to circumvent therapeutic resistance to EGFR targeting.
Kang and colleagues review recent advances and challenges in developing therapies for metastatic cancer and the clinical implications of ongoing and completed studies for metastatic disease.
Mukhopadhyay, Vander Heiden and McCormick review the metabolic landscape of RAS-driven cancers, the effects of RAS-directed metabolic reprogramming and opportunities for targeting these cancers therapeutically.
Edelman Saul and colleagues review the challenges and strategies for implementing low-dose computed tomography screening for lung cancer in low- and middle-income countries.
Zitvogel and colleagues discuss the interplay between cancer and COVID-19 with respect to patient risk and prognosis, immune responses and potential therapies.
Zhang and Meyerson review exciting advances in methodologies, models and datasets to study noncoding alterations in cancer, new insights into their roles in disease and potential translational implications.
Molecular characterization of tumors informs clinical cancer care. Here, Taylor and colleagues review the progress, opportunities, and challenges of scientific and translational discovery that leverages prospective data from clinical genomic screening.
Garnett and colleagues review principles that underpin the pre-clinical development of genomics-guided cancer medicines, challenges that limit their impact, and new opportunities, such as CRISPR-based screening, for refining and extending their use.
Evaluation of circulating tumor DNA in blood has emerged as a powerful technology for oncology research. Lillian Siu and colleagues review the potential applications of liquid biopsy, highlighting clinical-trial designs to establish its clinical utility.
